10/17/2008

The FDA has granted ImpediMed approval to market its L-Dex U400 device for use in assessing lymphoedema, a condition that affects women who underwent surgery for breast cancer. The clearance will grant the Australian firm access to the $4.4 billion international market for lymphoedema therapies.

Related Summaries